Sometimes you just have to sit tight and hold on, and that's exactly where I am at with both DXB and BOT. Yes, both have passed the 20% gain and so, under my plan, they should be sold. However, both still have significant movements to make in the near future. With BOT, we know the date: late June for FDA approval and a massive jump in the share price. With DXB: they are currently negotiating licencing deals for the USA and for China. As each of those deals gets signed, there will be large movements in the share price. But the timing is uncertain. All we know is that the boys are in the back room and cruching the numbers. In reality, a deal will not be far away at all. Plus... Looking at another one I recommended to a friend: AUQ. At the time of writing, sitting at 7.1 cents. I expect this one to improve by 50% in the next 2 months (roughly the same timeframe as BOT - although BOT has a much bigger upside). So, tke a deep breath and hold on, here's where the ride gets really ex...